{
  "schema_version": "0.1.0",
  "case_id": "HR-NI029",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "NI029",
    "display_name": "Higuchi Ichiyō",
    "aliases": [
      "Higuchi Natsu",
      "Higuchi Natsuko"
    ],
    "name_parts": {
      "given": [
        "Ichiyō"
      ],
      "family": "Higuchi",
      "family_first": true
    },
    "sex": "female",
    "era": "19th Century",
    "nationality": "Japanese",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1872-05-02",
          "display": "May 2, 1872",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1872-05-02",
              "display": "Meiji 5, 3rd month, 25th day (Japanese lunisolar calendar), given here as its Gregorian equivalent",
              "precision": "day",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0002"
            ],
            "resolution_status": "preferred",
            "note": "Japan used a lunisolar calendar until the end of Meiji 5 (the 3rd day of the 12th month became January 1, 1873). The Nipponica encyclopedia gives her birth as Meiji 5, 3rd month, 25th day, equal to May 2, 1872 in the Gregorian calendar, which the National Diet Library also gives."
          },
          {
            "date": {
              "iso": "1872",
              "display": "1872",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the National Diet Library."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1896-11-23",
          "display": "November 23, 1896",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1896",
              "display": "1896",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the National Diet Library."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-NI029-SYN",
      "ssn": "000-29-5108",
      "date_of_birth": "2002-05-02",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Aiko Lindgren-Tanaka, MD",
      "fictional_consultant": {
        "name": "Hiroshi Abernathy-Okoye, MD",
        "specialty": "Infectious Diseases (tuberculosis)"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1872-05-02",
        "display": "May 2, 1872",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Tokyo (Meiji 5, 3rd month, 25th day, in the lunisolar calendar).",
      "claim_ids": [
        "CLM-0001",
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1886",
        "display": "1886",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Begins the study of classical poetry at the Haginoya.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1889",
        "display": "summer 1889",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Her father dies; she becomes head of the household.",
      "claim_ids": [
        "CLM-0004"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1891",
        "display": "1891",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Becomes a pupil of Nakarai Tōsui and begins to write fiction.",
      "claim_ids": [
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1893-07",
        "display": "July 1893",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Opens a small shop in Shitaya Ryūsenji-chō beside the Yoshiwara; it closes in April 1894.",
      "claim_ids": [
        "CLM-0006"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1894-05",
        "display": "May 1894",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Moves to Hongō Maruyama-Fukuyama-chō; her major works follow.",
      "claim_ids": [
        "CLM-0007",
        "CLM-0008"
      ]
    },
    {
      "event_id": "EVT-0007",
      "date": {
        "iso": "1896-01",
        "display": "early 1896",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Her health declines rapidly.",
      "claim_ids": [
        "CLM-0010"
      ]
    },
    {
      "event_id": "EVT-0008",
      "date": {
        "iso": "1896-11-23",
        "display": "November 23, 1896",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Dies of tuberculosis at home in Hongō, at 24.",
      "claim_ids": [
        "CLM-0011",
        "CLM-0009"
      ]
    },
    {
      "event_id": "EVT-0009",
      "date": {
        "iso": "2004-11-01",
        "display": "November 1, 2004",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Her portrait appears on the new 5,000-yen note.",
      "claim_ids": [
        "CLM-0012"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Higuchi Ichiyō, whose given name was Natsu (also written Natsuko), was born in Tokyo on the 25th day of the 3rd month of Meiji 5 in the Japanese lunisolar calendar, which is 2 May 1872 in the Gregorian calendar, in official housing within the grounds of the Tokyo prefectural office in Uchisaiwai-chō (now in Chiyoda).",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "日本大百科全書(ニッポニカ): 明治5年3月25日（新暦5月2日）"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster birth year 1872"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "Japan replaced its lunisolar calendar with the Gregorian calendar at the end of Meiji 5: the 3rd day of the 12th month of Meiji 5 became 1 January 1873 (Meiji 6). Dates before then, including her birth, were recorded in the old calendar.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Explains why her birth date is given in two calendars.",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "From 1886 she studied classical poetry (waka) at the Haginoya academy of Nakajima Utako.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0004",
      "statement": "Her father died of illness in the summer of 1889, when she was 17, leaving debts from a failed business; she became head of the household and took on the support of her mother and younger sister, who did washing and needlework, and the family lived in poverty.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only; her mother and sister are given no role in the modern episode.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0005",
      "statement": "In 1891 she became a pupil of the novelist Nakarai Tōsui and began to write fiction, choosing to earn her living by writing at a time when this was very hard for a woman; her story Umoregi (1892) brought her into the literary world.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors her modern occupation as a writer.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0006",
      "statement": "From July 1893 to April 1894 she ran a small shop selling household goods and cheap sweets in Shitaya Ryūsenji-chō, beside the Yoshiwara pleasure quarter (now in Taitō); the shop closed after about ten months, and her life there became material for Takekurabe.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "In May 1894 she moved to Hongō Maruyama-Fukuyama-chō (now Nishikata, Bunkyō).",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the place of the index date.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0008",
      "statement": "At Maruyama-Fukuyama-chō she wrote the works that made her name, among them Ōtsugomori (1894), Nigorie (1895), Takekurabe (1895 to 1896) and Jūsan'ya; Nippon.com calls the period 'the miraculous 14 months', and the Nipponica encyclopedia calls the time up to January 1896 'the miraculous year'.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the modern episode's attention to her writing; the two sources measure the period differently.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0009",
      "statement": "She died in poverty.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the low income in the modern social history.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0010",
      "statement": "From the beginning of 1896 her health declined rapidly.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the index date and the presenting illness.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0011",
      "statement": "She died of tuberculosis on 23 November 1896 at her home in Hongō, at the age of 24. The National Diet Library gives the cause as lung tuberculosis; the Nipponica encyclopedia gives miliary tuberculosis.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "After the index date. Tuberculosis is documented; the sources differ on its form (pulmonary or miliary), so the modern pulmonary diagnosis is linked to the documented disease, not to either form.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0012",
      "statement": "Her portrait appears on the Bank of Japan 5,000-yen note first issued on 1 November 2004, whose back shows Ogata Kōrin's painting of irises; a new 5,000-yen note with a different portrait was first issued on 3 July 2024.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only.",
      "source_links": [
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "Portraits of Modern Japanese Historical Figures: HIGUCHI Ichiyo",
      "publisher": "National Diet Library, Japan",
      "url": "https://www.ndl.go.jp/portrait/e/datas/315.html",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "National library biography; facts used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "樋口一葉 (Higuchi Ichiyō), entries from 日本大百科全書(ニッポニカ), 世界大百科事典 and デジタル版 日本人名大辞典+Plus",
      "publisher": "Kotobank (Asahi Shimbun), carrying Shogakukan, Heibonsha and Kodansha reference works",
      "url": "https://kotobank.jp/word/%E6%A8%8B%E5%8F%A3%E4%B8%80%E8%91%89-17510",
      "source_type": "scholarly",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Encyclopedia entries in Japanese; facts translated and used with citation."
    },
    {
      "source_id": "SRC-0003",
      "title": "Higuchi Ichiyō (Shapers of Japanese History)",
      "publisher": "Nippon.com (Nippon Communications Foundation)",
      "url": "https://www.nippon.com/en/japan-topics/b07226/",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Biographical article; facts used with citation."
    },
    {
      "source_id": "SRC-0004",
      "title": "Ichiyo Memorial Museum",
      "publisher": "Taito City Culture Foundation (Ichiyō Memorial Museum, Taitō, Tokyo)",
      "url": "https://taitogeibun.net/english/ichiyo",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Museum page; facts used with citation."
    },
    {
      "source_id": "SRC-0005",
      "title": "Bank of Japan Notes and Coins Currently Issued",
      "publisher": "Bank of Japan",
      "url": "https://www.boj.or.jp/en/note_tfjgs/note/valid/issue.htm",
      "source_type": "other",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Central bank reference page; facts used with citation."
    },
    {
      "source_id": "SRC-0006",
      "title": "Calendar History 2 (The Japanese Calendar)",
      "publisher": "National Diet Library, Japan",
      "url": "https://www.ndl.go.jp/koyomi/e/history/calendar.html",
      "source_type": "scholarly",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "National library exhibition page; one fact used with citation."
    },
    {
      "source_id": "SRC-0007",
      "title": "樋口一葉 (Higuchi Ichiyō), 文京ゆかりの文人",
      "publisher": "Bunkyō City, Tokyo",
      "url": "https://www.city.bunkyo.lg.jp/b014/p003900.html",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Municipal biography in Japanese; facts translated and used with citation."
    },
    {
      "source_id": "SRC-0009",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-05",
      "accessed": "2026-11-05",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-04-14",
    "index_age": 23,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "Recognize and treat pulmonary tuberculosis in a 23-year-old writer in Tokyo with a low income, inside Japan's public health system: seven weeks of cough, fevers, night sweats and weight loss resolved into a diagnosis by chest X-ray, three sputum specimens for acid-fast smear, Xpert MTB/RIF Ultra with rifampin resistance, liquid culture and drug susceptibility testing; HIV, hepatitis and pregnancy testing, baseline liver tests, vision testing before ethambutol, and diabetes screening; airborne precautions and immediate notification to the public health center under the Infectious Diseases Control Law; outpatient care with public funding for a smear-negative patient; the choice of the standard six-month regimen (isoniazid, rifampin, pyrazinamide and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks) because her weight is below the 40 kg needed for the four-month rifapentine-moxifloxacin regimen; daily video-observed therapy with pyridoxine; monitoring for liver injury and optic neuropathy; a contact investigation of her household led by the public health center; treatment of moderate malnutrition and help with income; contraception counseling for rifampin interactions; and a paced plan that lets her keep writing. The modern episode is a teaching case, not a claim about her real illness or care.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-04-14",
        "purpose": "New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-04-17",
        "purpose": "Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimen"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-05-01",
        "purpose": "Two-week review on treatment: culture result, liver tests, vision, and release from precautions"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-06-12",
        "purpose": "End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase"
      },
      {
        "encounter_id": "ENC-006",
        "date": "2026-07-20",
        "purpose": "Same-day sick visit for acute cystitis during tuberculosis treatment"
      },
      {
        "encounter_id": "ENC-007",
        "date": "2026-08-24",
        "purpose": "Periodic adult preventive visit"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-10-20",
        "purpose": "End-of-treatment review after 182 doses"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R05.3",
            "display": "Chronic cough",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "abatement_date": "2026-04-17"
      },
      {
        "id": "PRB-002",
        "display": "Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "A15.0",
            "display": "Tuberculosis of lung",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-04-17",
        "abatement_date": "2026-10-20"
      },
      {
        "id": "PRB-003",
        "display": "Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E44.0",
            "display": "Moderate protein-calorie malnutrition",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic nutrition diagnosis at intake, anchored to her documented poverty.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "abatement_date": "2026-10-20"
      },
      {
        "id": "PRB-004",
        "display": "Low and irregular income from writing, with a household to support; costs of care are a barrier",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "Z59.6",
            "display": "Low income",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic social need anchored to her documented poverty and household responsibilities.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-005",
        "display": "Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolved",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "N30.00",
            "display": "Acute cystitis without hematuria",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic intercurrent illness; not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-07-20",
        "abatement_date": "2026-08-24"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Isoniazid 100 mg tablets, two tablets (200 mg) daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "311166",
            "display": "isoniazid 100 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 200,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks"
        },
        "start_date": "2026-04-17",
        "end_date": "2026-10-15",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic standard regimen (about 5 mg/kg) for drug-susceptible pulmonary tuberculosis.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "198201",
            "display": "rifampin 150 MG Oral Capsule",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 450,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks"
        },
        "start_date": "2026-04-17",
        "end_date": "2026-10-15",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic standard regimen (about 10 to 12 mg/kg).",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "198181",
            "display": "pyrazinamide 500 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1000,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase"
        },
        "start_date": "2026-04-17",
        "end_date": "2026-06-11",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic weight-based dose (about 25 mg/kg) for the intensive phase.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Ethambutol 100 mg tablets, six tablets (600 mg) daily",
        "status": "stopped",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "995599",
            "display": "ethambutol hydrochloride 100 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 600,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return"
        },
        "start_date": "2026-04-17",
        "end_date": "2026-05-22",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic weight-based dose (about 15 mg/kg); stopped when the isolate proved susceptible to isoniazid and rifampin.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "639566",
            "display": "vitamin B6 50 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 50,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "50 mg once daily with isoniazid"
        },
        "start_date": "2026-04-17",
        "end_date": "2026-10-15",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic neuropathy prevention with isoniazid in an undernourished woman of childbearing age.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MED-006",
        "display": "Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five days",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1648755",
            "display": "nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "One capsule twice daily with food for five days"
        },
        "start_date": "2026-07-20",
        "end_date": "2026-07-24",
        "indication_problem_ids": [
          "PRB-005"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first-line treatment for acute uncomplicated cystitis (IDSA 2010); no interaction with isoniazid or rifampin; eGFR well above 30.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 11.4,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "L",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V1",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 8.6,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V1",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 452,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "H",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 12,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 19,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V1",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 0.4,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V1",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 74,
        "unit": "U/L",
        "reference_range": {
          "low": 35,
          "high": 104
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V1",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 3.3,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 0.56,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.5,
          "high": 1.0
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 131,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V1",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 82,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V1",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-04-14",
        "value": 5.1,
        "unit": "%",
        "reference_range": {
          "high": 5.6,
          "text": "Below 5.7% is normal; 6.5% or more is diabetes"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic baseline result before tuberculosis treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOD-V1",
        "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
        "label": "Visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-04-14",
        "value": 85,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79878-5",
            "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline uncorrected acuity before ethambutol (85 letters, about 20/20).",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOS-V1",
        "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
        "label": "Visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-04-14",
        "value": 85,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79879-3",
            "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline uncorrected acuity before ethambutol.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V1",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-04-14",
        "value": 8,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen: tiredness, poor sleep from night sweats and coughing, poor appetite, and worry about money and her household; item 9 scored 0. Not a claim about her real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-V1",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-04-14",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol screen; she does not drink.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V3",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-01",
        "value": 22,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic two-week liver check, planned because of her low weight and albumin.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V3",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-01",
        "value": 24,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic two-week liver check, planned because of her low weight and albumin.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V3",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-01",
        "value": 0.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic two-week liver check, planned because of her low weight and albumin.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOD-V3",
        "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
        "label": "Visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-01",
        "value": 85,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79878-5",
            "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic acuity check on ethambutol.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOS-V3",
        "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
        "label": "Visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-01",
        "value": 84,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79879-3",
            "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic acuity check on ethambutol; unchanged within test variability.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V4",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-12",
        "value": 26,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-intensive-phase result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V4",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-12",
        "value": 25,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-intensive-phase result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V4",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-12",
        "value": 0.5,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-intensive-phase result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V4",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-12",
        "value": 3.8,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-intensive-phase result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V4",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-12",
        "value": 12.4,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-intensive-phase result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOD-V4",
        "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
        "label": "Visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-06-12",
        "value": 85,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79878-5",
            "display": "Visual acuity uncorrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic acuity three weeks after ethambutol was stopped.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAOS-V4",
        "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
        "label": "Visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-06-12",
        "value": 85,
        "unit": "{letters}",
        "reference_range": {
          "low": 80
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79879-3",
            "display": "Visual acuity uncorrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic acuity three weeks after ethambutol was stopped.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V4",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-06-12",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9 at two months; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V5",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 18,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-treatment result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V5",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 20,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-treatment result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V5",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 4.2,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-treatment result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V5",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 13.2,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-treatment result.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V5",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-10-20",
        "value": 3,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic end-of-treatment mood screen; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V7",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-08-24",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen; negative.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-GAD7-V7",
        "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
        "label": "GAD-7",
        "status": "final",
        "effective_date": "2026-08-24",
        "value": 4,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "70274-6",
            "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic anxiety screen; minimal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-V7",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-08-24",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol screen; does not drink.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-001",
        "display": "Chest X-ray, two views: patchy opacities in the apical and posterior segments of the right upper lobe with small nodules; no cavity, effusion or hilar enlargement",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "399208008",
            "display": "Plain X-ray of chest",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-04-14",
          "end": "2026-04-14"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic diagnostic chest X-ray.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "Chest X-ray, two views, at the end of treatment: right upper lobe opacities cleared, leaving a few linear scars; kept as the baseline for any future comparison",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "399208008",
            "display": "Plain X-ray of chest",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-10-20",
          "end": "2026-10-20"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic end-of-treatment chest X-ray.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "PROC-003",
        "display": "Cervical cytology (Papanicolaou test), first screening",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "439958008",
            "display": "Sampling of cervix for Papanicolaou smear",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-08-24",
          "end": "2026-08-24"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic cervical screening at 24, with her consent after explanation; result negative for intraepithelial lesion or malignancy, reported by phone.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "PROC-004",
        "display": "Advance care planning conversation, about 16 minutes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-08-24",
          "end": "2026-08-24"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic voluntary advance care planning; records only her own general preferences.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)",
        "status": "completed",
        "date": "2026-08-24",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "115",
            "display": "Tdap",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic Tdap; childhood doses recorded but no adult booster.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "Hepatitis B vaccine (HepB-CpG), dose 1 of 2",
        "status": "completed",
        "date": "2026-08-24",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hepatitis B vaccination; screening at intake showed no immunity.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "Human papillomavirus 9-valent vaccine, dose 1 of 3",
        "status": "completed",
        "date": "2026-08-24",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "165",
            "display": "HPV9",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic catch-up HPV vaccination at 24, with no record of earlier doses.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "IMM-004",
        "display": "Hepatitis B vaccine (HepB-CpG), dose 2 of 2",
        "status": "completed",
        "date": "2026-10-20",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second dose eight weeks after the first.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "IMM-005",
        "display": "Human papillomavirus 9-valent vaccine, dose 2 of 3",
        "status": "completed",
        "date": "2026-10-20",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "165",
            "display": "HPV9",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second dose eight weeks after the first; dose 3 due six months after dose 1.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "IMM-006",
        "display": "Influenza vaccine, inactivated, trivalent, preservative-free",
        "status": "completed",
        "date": "2026-10-20",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "140",
            "display": "Influenza, split virus, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seasonal influenza vaccination in the autumn.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "family_history": [
      {
        "id": "FH-001",
        "relationship": {
          "system": "http://terminology.hl7.org/CodeSystem/v3-RoleCode",
          "code": "FTH",
          "display": "father"
        },
        "condition": "Died of illness in 1889; cause not recorded in the cited source",
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "past_medical_history": [],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center",
        "status": "finished",
        "date": "2026-04-14",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimen",
        "status": "finished",
        "date": "2026-04-17",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Results visit: sputum tests, with infectious diseases consultation the same day",
          "hpi": {
            "narrative": "Ms. Higuchi returns three days after her first visit for her results and is seen by Dr. Abernathy-Okoye of infectious diseases today. She brought the second and third sputum specimens, the last collected on waking this morning. Since her first visit she has stayed home, slept in her own room with the window open, and worn a surgical mask in the shared rooms; no one has visited. The cough is unchanged, with a little white sputum and no blood, and she still has evening fevers and night sweats. She is eating a little more since the dietitian's first call. She has not written since her first visit. She is worried about the people she lives with and about the cost of treatment.",
            "elements": [
              {
                "label": "Symptoms",
                "value": "Cough, evening fevers and night sweats unchanged; no hemoptysis"
              },
              {
                "label": "Precautions",
                "value": "At home with a mask in shared rooms; no visitors"
              },
              {
                "label": "Testing",
                "value": "Three sputum specimens complete; blood results back"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Cough with a little white sputum; no blood; breathless on the stairs"
            },
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Evening fevers, night sweats and tiredness"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No blurred vision"
            },
            {
              "system": "Psychiatric",
              "status": "positive",
              "finding": "Worried about her household and costs; no thoughts of self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Thin and tired; weight 38.4 kg; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room with staff wearing respirators"
            },
            {
              "system": "Respiratory",
              "finding": "Fine crackles over the right upper zone; no wheeze"
            },
            {
              "system": "Eyes",
              "finding": "No icterus"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; liver not enlarged"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, smear-negative, Xpert-confirmed",
              "assessment": "All three sputum smears are negative for acid-fast bacilli, but Xpert MTB/RIF Ultra on the first specimen detected Mycobacterium tuberculosis at a low level with no rifampin resistance, which with her symptoms and the right upper lobe opacities confirms pulmonary tuberculosis. Cultures and susceptibility testing are pending. HIV, hepatitis B surface antigen, hepatitis C antibody and the pregnancy test are negative. Liver and kidney tests are normal, hemoglobin A1c 5.1%, and visual acuity 85 letters in each eye with normal color vision. At 38.5 kg she is below the 40 kg needed for the four-month rifapentine-moxifloxacin regimen, so the standard six-month regimen is used. Dr. Abernathy-Okoye agrees the regimen, doses and monitoring",
              "plan": [
                "Isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily, with pyridoxine 50 mg, from today; first dose taken in the clinic",
                "Daily video-observed therapy with the public health center from tomorrow",
                "Notification to the public health center today",
                "Liver tests and vision at two weeks; call the same day for nausea, vomiting, abdominal pain, yellow eyes, dark urine or any change in vision",
                "Expect orange urine and tears"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Moderate protein-calorie malnutrition",
              "assessment": "Weight 38.4 kg; eating slightly more",
              "plan": [
                "Second dietitian visit next week; supplement drinks twice daily"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Low income",
              "assessment": "Treatment costs are her main fear. Outpatient tuberculosis drugs, X-rays and sputum tests qualify for public funding of 95 percent under the Infectious Diseases Control Law",
              "plan": [
                "Medical social worker to complete the public funding application with her today"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Sputum smear and culture",
              "cadence": "At diagnosis, at two weeks, and at the end of the intensive phase (two months)",
              "status": "completed_today",
              "detail": "Three specimens, one on waking: smears negative for acid-fast bacilli; liquid and solid cultures pending",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Xpert MTB/RIF Ultra (nucleic acid amplification with rifampin resistance)",
              "cadence": "At diagnosis",
              "status": "completed_today",
              "detail": "Mycobacterium tuberculosis detected, low; rifampin resistance not detected",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Drug susceptibility testing of the first isolate",
              "cadence": "Once, on the first positive culture",
              "status": "ordered",
              "detail": "Phenotypic susceptibility to first-line drugs to be set up on the first positive culture",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "HIV test",
              "cadence": "At diagnosis",
              "status": "up_to_date",
              "detail": "HIV-1/2 antigen and antibody test negative",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hepatitis B and C serology",
              "cadence": "At diagnosis",
              "status": "up_to_date",
              "detail": "Hepatitis B surface antigen, surface antibody and core antibody negative (not immune); hepatitis C antibody negative",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Pregnancy test",
              "cadence": "Before starting treatment in a woman who could be pregnant",
              "status": "up_to_date",
              "detail": "Negative at intake",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Diabetes screen (hemoglobin A1c)",
              "cadence": "At diagnosis",
              "status": "up_to_date",
              "detail": "5.1% at intake",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests (ALT, AST, bilirubin)",
              "cadence": "Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms",
              "status": "up_to_date",
              "detail": "Normal at intake (ALT 12, AST 19 U/L, bilirubin 0.4 mg/dL); albumin 3.3 g/dL",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Visual acuity and color vision",
              "cadence": "Baseline and monthly while on ethambutol",
              "status": "up_to_date",
              "detail": "85 letters in each eye with normal color vision at intake, before ethambutol",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Chest X-ray",
              "cadence": "At diagnosis and at the end of treatment as a new baseline",
              "status": "up_to_date",
              "detail": "Right upper lobe opacities without a cavity at intake",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Regimen choice and weight-based doses",
              "cadence": "At the start of treatment",
              "status": "completed_today",
              "detail": "Standard six-month regimen; not eligible for the four-month rifapentine-moxifloxacin regimen at 38.5 kg. Isoniazid 5, rifampin 12, pyrazinamide 26 and ethambutol 16 mg/kg",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-TB-2025",
                "GL-CDC-4MO-2022",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Doses observed and missed (video-observed therapy)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "First dose observed in the clinic; video-observed therapy from tomorrow",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Rifampin drug-interaction review, including hormonal contraception",
              "cadence": "With every new medicine",
              "status": "completed_today",
              "detail": "No other medicines; told that rifampin weakens hormonal contraceptives and interacts with many drugs",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Home precautions and the criteria for release",
              "cadence": "Until two weeks of treatment with clinical improvement, for smear-negative disease",
              "status": "completed_today",
              "detail": "Precautions at home continue; smear-negative, so treated as an outpatient",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "referral",
              "measure": "Notification to the public health center (Infectious Diseases Control Law, Article 12)",
              "cadence": "At once on diagnosis",
              "status": "completed_today",
              "detail": "Notified today; the center was told of the suspected case at intake",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY"
              ]
            },
            {
              "domain": "referral",
              "measure": "Contact investigation (household and close contacts)",
              "cadence": "Led by the public health center, from diagnosis",
              "status": "referred",
              "detail": "The public health center will assess her household and close contacts; their results belong to their own records",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005"
              ]
            },
            {
              "domain": "referral",
              "measure": "Public funding and other help with costs",
              "cadence": "At diagnosis",
              "status": "completed_today",
              "detail": "Public funding application completed with the social worker",
              "guideline_ids": [
                "GL-JP-TB-FUNDING"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Weight and nutrition",
              "cadence": "Every visit; dose review if weight changes by more than about 5 kg",
              "status": "completed_today",
              "detail": "38.4 kg; dietitian and supplement drinks",
              "guideline_ids": [
                "GL-ASPEN-MALN-2012"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At diagnosis, at two months, and at the end of treatment",
              "status": "up_to_date",
              "detail": "PHQ-9 8 at intake, item 9 scored 0",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "referral",
              "measure": "Infectious diseases consultation",
              "cadence": "Once at diagnosis, then as advised",
              "status": "completed_today",
              "detail": "Seen today by Dr. Abernathy-Okoye",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-TB-2025"
              ]
            }
          ],
          "follow_up": "Two-week review with liver tests, vision and a sputum specimen. Call the same day for hepatitis symptoms or any change in vision",
          "guideline_ids": [
            "GL-ATS-TB-2016",
            "GL-ATS-TB-2025",
            "GL-WHO-TB-2022",
            "GL-ATS-TBDX-2017",
            "GL-CDC-4MO-2022",
            "GL-ATS-HEPATOTOX-2006",
            "GL-CDC-CONTACT-2005",
            "GL-MHLW-TB-NOTIFY",
            "GL-JP-TB-FUNDING",
            "GL-ASPEN-MALN-2012"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Two-week review on treatment: culture result, liver tests, vision, and release from precautions",
        "status": "finished",
        "date": "2026-05-01",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Two-week review on tuberculosis treatment",
          "hpi": {
            "narrative": "Ms. Higuchi returns two weeks into treatment. She has taken all fourteen doses on daily video calls with the public health center nurse. The evening fevers stopped about ten days in, the night sweats are lighter, and the cough is less frequent and dry. She had mild nausea after the morning doses in the first week, which went once she moved them to bedtime with a small snack. Her urine and tears are orange, as expected. She has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or colors. The liquid culture from her first sputum specimen grew Mycobacterium tuberculosis complex after twelve days. She is eating three meals and two snacks a day with the supplement drinks. The public funding was approved. She has begun to write again for about an hour each morning.",
            "elements": [
              {
                "label": "Treatment",
                "value": "Fourteen of fourteen doses observed by video"
              },
              {
                "label": "Symptoms",
                "value": "No fever for four days; lighter night sweats; less cough"
              },
              {
                "label": "Side effects",
                "value": "Mild nausea in the first week, gone with bedtime dosing; orange urine and tears"
              },
              {
                "label": "Culture",
                "value": "Mycobacterium tuberculosis complex grown from the first specimen"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Occasional dry cough; no blood; less breathless"
            },
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Lighter night sweats; no fever for four days; appetite better"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No nausea now; no vomiting, abdominal pain or jaundice"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No blurred vision or change in colors"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No numbness or tingling"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Less tired; weight 39.2 kg, up 0.7 kg; temperature 37.1 °C, pulse 90"
            },
            {
              "system": "Eyes",
              "finding": "No icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye"
            },
            {
              "system": "Respiratory",
              "finding": "A few fine crackles over the right upper zone, fewer than at diagnosis"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; liver not enlarged"
            },
            {
              "system": "Neurological",
              "finding": "Normal sensation and reflexes in the feet"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, intensive phase",
              "assessment": "Culture-confirmed, with a clear clinical response and full adherence. ALT 22, AST 24 and bilirubin 0.6 at two weeks, all normal. Vision unchanged on ethambutol. Susceptibility testing is under way on the isolate. With smear-negative disease, two weeks of effective treatment and improvement, the public health center agrees she is no longer considered infectious and may end the home precautions",
              "plan": [
                "Continue the four drugs and pyridoxine daily by video-observed therapy, at bedtime",
                "Stop ethambutol by phone once the isolate is shown to be susceptible to isoniazid and rifampin",
                "Sputum specimen today for smear and culture; another at two months",
                "Monthly liver tests in the intensive phase; call the same day for hepatitis symptoms or any change in vision"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Moderate protein-calorie malnutrition, improving",
              "assessment": "Weight 39.2 kg, up 0.7 kg",
              "plan": [
                "Continue the meal plan and supplement drinks"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Low income",
              "assessment": "Public funding approved for her tuberculosis care",
              "plan": [
                "Social worker to help with the remaining clinic charges"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "Symptom review: cough, sputum, fever, night sweats",
              "cadence": "At least monthly during treatment",
              "status": "completed_today",
              "detail": "No fever for four days; lighter night sweats; occasional dry cough",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Weight and nutrition",
              "cadence": "Every visit; dose review if weight changes by more than about 5 kg",
              "status": "completed_today",
              "detail": "39.2 kg, up 0.7 kg; doses unchanged",
              "guideline_ids": [
                "GL-ASPEN-MALN-2012",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)",
              "cadence": "Every visit and every observed dose",
              "status": "completed_today",
              "detail": "Mild nausea in the first week only; no jaundice, dark urine or pain",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests (ALT, AST, bilirubin)",
              "cadence": "Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms",
              "status": "completed_today",
              "detail": "ALT 22, AST 24 U/L, bilirubin 0.6 mg/dL, all normal",
              "observation_ids": [
                "OBS-ALT-V3",
                "OBS-AST-V3",
                "OBS-TBIL-V3"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Visual acuity and color vision",
              "cadence": "Baseline and monthly while on ethambutol",
              "status": "completed_today",
              "detail": "85 letters on the right and 84 on the left; color vision normal",
              "observation_ids": [
                "OBS-VAOD-V3",
                "OBS-VAOS-V3"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Sputum smear and culture",
              "cadence": "At diagnosis, at two weeks, and at the end of the intensive phase (two months)",
              "status": "completed_today",
              "detail": "Liquid culture of the first specimen grew Mycobacterium tuberculosis complex at twelve days; two-week specimen sent today",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Drug susceptibility testing of the first isolate",
              "cadence": "Once, on the first positive culture",
              "status": "ordered",
              "detail": "Set up on the isolate; result expected in about three weeks",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Doses observed and missed (video-observed therapy)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Fourteen of fourteen doses observed",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Peripheral neuropathy check, with pyridoxine",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No neuropathy; pyridoxine 50 mg daily",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Rifampin drug-interaction review, including hormonal contraception",
              "cadence": "With every new medicine",
              "status": "completed_today",
              "detail": "No new medicines",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Home precautions and the criteria for release",
              "cadence": "Until two weeks of treatment with clinical improvement, for smear-negative disease",
              "status": "completed_today",
              "detail": "Released from home precautions today with the public health center's agreement",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "referral",
              "measure": "Contact investigation (household and close contacts)",
              "cadence": "Led by the public health center, from diagnosis",
              "status": "referred",
              "detail": "Under way with the public health center; results not part of her record",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005"
              ]
            },
            {
              "domain": "referral",
              "measure": "Public funding and other help with costs",
              "cadence": "At diagnosis and as needed",
              "status": "completed_today",
              "detail": "Public funding approved",
              "guideline_ids": [
                "GL-JP-TB-FUNDING"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At diagnosis, at two months, and at the end of treatment",
              "status": "up_to_date",
              "detail": "PHQ-9 8 at intake; next at two months",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            }
          ],
          "follow_up": "Ethambutol stopped by phone when susceptibility results return. Monthly liver tests. End-of-intensive-phase review at eight weeks with the two-month sputum. Call the same day for hepatitis symptoms or any change in vision",
          "guideline_ids": [
            "GL-ATS-TB-2016",
            "GL-WHO-TB-2022",
            "GL-ATS-TBDX-2017",
            "GL-ATS-HEPATOTOX-2006",
            "GL-CDC-CONTACT-2005",
            "GL-MHLW-TB-NOTIFY",
            "GL-JP-TB-FUNDING",
            "GL-ASPEN-MALN-2012"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase",
        "status": "finished",
        "date": "2026-06-12",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "End of the eight-week intensive phase",
          "hpi": {
            "narrative": "Ms. Higuchi returns at the end of the intensive phase, having taken all 56 doses by video, the last pyrazinamide dose yesterday. The isolate was susceptible to isoniazid, rifampin, pyrazinamide and ethambutol, and ethambutol was stopped by phone three weeks ago when the result arrived. The two-week sputum showed no acid-fast bacilli, and its culture has had no growth. The cough has gone and the night sweats stopped a month ago. She has no nausea, yellowing, dark urine, abdominal pain, numbness, or change in vision. She is eating well and has gained 2.5 kg. She is writing two hours each morning and has sent a story to an editor.",
            "elements": [
              {
                "label": "Treatment",
                "value": "56 of 56 intensive-phase doses observed; ethambutol stopped three weeks ago"
              },
              {
                "label": "Susceptibility",
                "value": "Susceptible to all four first-line drugs"
              },
              {
                "label": "Symptoms",
                "value": "No cough or night sweats"
              },
              {
                "label": "Weight",
                "value": "41.0 kg, up 2.5 kg"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or sputum; not breathless"
            },
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever or night sweats; energy better"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No nausea, abdominal pain or jaundice"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No change in vision or colors"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood better; PHQ-9 5"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Looks well; weight 41.0 kg, BMI 18.7; temperature 36.8 °C, pulse 80"
            },
            {
              "system": "Eyes",
              "finding": "No icterus. Visual acuity 85 letters in each eye; Ishihara plates normal"
            },
            {
              "system": "Respiratory",
              "finding": "Clear on both sides"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender"
            },
            {
              "system": "Neurological",
              "finding": "Normal sensation in the feet"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, drug-susceptible, end of the intensive phase",
              "assessment": "Excellent clinical response with full adherence. ALT 26, AST 25, bilirubin 0.5, all normal. Without a cavity on the first X-ray, the continuation phase is four months. If the two-month culture were positive, extension to seven months would be considered because she is underweight; it is not changed while that culture is pending",
              "plan": [
                "Isoniazid 200 mg, rifampin 450 mg and pyridoxine 50 mg daily by video-observed therapy for eighteen weeks from today",
                "Pyrazinamide finished yesterday",
                "Induced sputum today for the two-month smear and culture",
                "In the continuation phase, liver tests only for symptoms, since the tests stayed normal and albumin has recovered; the observing nurse asks about symptoms at each dose"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Moderate protein-calorie malnutrition, improving",
              "assessment": "Weight 41.0 kg and albumin 3.8 g/dL; hemoglobin 12.4 g/dL, up from 11.4 as the infection settles",
              "plan": [
                "Continue the meal plan and supplement drinks"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "Symptom review: cough, sputum, fever, night sweats",
              "cadence": "At least monthly during treatment",
              "status": "completed_today",
              "detail": "No cough, fever or night sweats",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Weight and nutrition",
              "cadence": "Every visit; dose review if weight changes by more than about 5 kg",
              "status": "completed_today",
              "detail": "41.0 kg, up 2.5 kg; albumin 3.8 g/dL; doses unchanged",
              "observation_ids": [
                "OBS-ALB-V4"
              ],
              "guideline_ids": [
                "GL-ASPEN-MALN-2012",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)",
              "cadence": "Every visit and every observed dose",
              "status": "completed_today",
              "detail": "No symptoms",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests (ALT, AST, bilirubin)",
              "cadence": "Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms",
              "status": "completed_today",
              "detail": "ALT 26, AST 25 U/L, bilirubin 0.5 mg/dL, all normal",
              "observation_ids": [
                "OBS-ALT-V4",
                "OBS-AST-V4",
                "OBS-TBIL-V4"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Monthly liver tests in the intensive phase (month one)",
              "cadence": "Monthly in the intensive phase because of low weight and albumin",
              "status": "deferred",
              "detail": "Missed: the liver tests due about four weeks into treatment were not drawn, because no visit was booked and the phone call that stopped ethambutol did not include a blood test. No harm judging by today's normal results and the absence of symptoms at every observed dose. Corrective action: blood tests due between visits are now booked as laboratory visits with a reminder to the observing nurse",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Visual acuity and color vision",
              "cadence": "Baseline and monthly while on ethambutol",
              "status": "deferred",
              "detail": "Missed: the monthly vision check due about four weeks into treatment, while she was still taking ethambutol, was not done for the same reason. No harm: acuity 85 letters in each eye and normal color vision today, three weeks after ethambutol was stopped. Corrective action: any future ethambutol course is booked with monthly vision checks",
              "observation_ids": [
                "OBS-VAOD-V4",
                "OBS-VAOS-V4"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Drug susceptibility testing of the first isolate",
              "cadence": "Once, on the first positive culture",
              "status": "completed_today",
              "detail": "Susceptible to isoniazid, rifampin, pyrazinamide and ethambutol; ethambutol stopped three weeks ago",
              "guideline_ids": [
                "GL-ATS-TBDX-2017",
                "GL-ATS-TB-2016"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Two-month sputum smear and culture",
              "cadence": "At the end of the intensive phase",
              "status": "completed_today",
              "detail": "Two-week specimen smear-negative with no growth so far; two-month induced specimen sent today",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-TB-2025"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count",
              "cadence": "At diagnosis, then as needed",
              "status": "completed_today",
              "detail": "Hemoglobin 12.4 g/dL, up from 11.4",
              "observation_ids": [
                "OBS-HGB-V4"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Continuation-phase length",
              "cadence": "At the end of the intensive phase",
              "status": "completed_today",
              "detail": "Four months planned, because there was no cavity; extension to seven months would be considered if the two-month culture were positive, because she is underweight",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Doses observed and missed (video-observed therapy)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "56 of 56 doses observed",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Peripheral neuropathy check, with pyridoxine",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No neuropathy; pyridoxine continues",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Rifampin drug-interaction review, including hormonal contraception",
              "cadence": "With every new medicine",
              "status": "completed_today",
              "detail": "No new medicines",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Contact investigation (household and close contacts)",
              "cadence": "Led by the public health center, from diagnosis",
              "status": "referred",
              "detail": "Continuing with the public health center; results not part of her record",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At diagnosis, at two months, and at the end of treatment",
              "status": "completed_today",
              "detail": "PHQ-9 5, from 8; item 9 scored 0",
              "observation_ids": [
                "OBS-PHQ9-V4"
              ],
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            }
          ],
          "follow_up": "Two-month culture result by phone. Preventive visit as booked. End-of-treatment visit after the 182nd dose. Call for cough, fever, weight loss, hepatitis symptoms or numbness",
          "guideline_ids": [
            "GL-ATS-TB-2016",
            "GL-ATS-TB-2025",
            "GL-WHO-TB-2022",
            "GL-ATS-TBDX-2017",
            "GL-ATS-HEPATOTOX-2006",
            "GL-CDC-CONTACT-2005",
            "GL-MHLW-TB-NOTIFY",
            "GL-ASPEN-MALN-2012",
            "GL-USPSTF-DEP-2023"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "End-of-treatment review after 182 doses",
        "status": "finished",
        "date": "2026-10-20",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "End-of-treatment review after six months",
          "hpi": {
            "narrative": "Ms. Higuchi returns having completed treatment five days ago: all 182 doses were observed by video, 56 in the intensive phase and 126 in the continuation phase, with none missed. The two-month sputum culture showed no growth. She has had no cough, fever or night sweats for four months and has gained 5.5 kg since intake. She has had no nausea, yellowing, numbness or change in vision. The cystitis in the summer did not return. The public health center has told her that its contact investigation is complete. She writes each morning and has finished two stories since the summer. Her cervical cytology was normal.",
            "elements": [
              {
                "label": "Treatment",
                "value": "182 of 182 doses observed; completed five days ago"
              },
              {
                "label": "Bacteriology",
                "value": "Two-week and two-month cultures negative"
              },
              {
                "label": "Weight",
                "value": "44.0 kg, up 5.5 kg from intake"
              },
              {
                "label": "Writing",
                "value": "Two new stories finished"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough, sputum or breathlessness"
            },
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, night sweats or weight loss"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No nausea or jaundice"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No numbness or tingling"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood good; PHQ-9 3"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 44.0 kg, BMI 20.1; temperature 36.5 °C, pulse 72, blood pressure 106/68"
            },
            {
              "system": "Eyes",
              "finding": "No icterus"
            },
            {
              "system": "Respiratory",
              "finding": "Clear on both sides"
            },
            {
              "system": "Abdomen",
              "finding": "Soft; liver not enlarged"
            },
            {
              "system": "Neurological",
              "finding": "Normal sensation and reflexes in the feet"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, treatment completed",
              "assessment": "Treatment completed with full observed adherence, culture conversion by two weeks, clinical cure, and normal liver tests throughout. The chest X-ray shows the right upper lobe opacities cleared, leaving a few linear scars; it is kept as her new baseline. Relapse after a fully observed course for drug-susceptible disease is uncommon, so no routine sputum follow-up is needed",
              "plan": [
                "Stop isoniazid, rifampin and pyridoxine",
                "Return for a cough lasting more than two to three weeks, fevers, night sweats or weight loss, and tell future clinicians she has been treated for tuberculosis",
                "The orange color of urine and tears will fade within days",
                "Hormonal contraception becomes reliable again about four weeks after the last rifampin dose"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Moderate protein-calorie malnutrition, resolved",
              "assessment": "Weight 44.0 kg, BMI 20.1, albumin 4.2 g/dL, hemoglobin 13.2 g/dL",
              "plan": [
                "Stop the supplement drinks; keep three meals a day"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Low income",
              "assessment": "Public funding has ended with treatment; she has paid her clinic charges in instalments",
              "plan": [
                "Social worker review of her health insurance premiums and any further help"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "Symptom review: cough, sputum, fever, night sweats",
              "cadence": "At least monthly during treatment",
              "status": "completed_today",
              "detail": "No symptoms for four months",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Weight and nutrition",
              "cadence": "Every visit; dose review if weight changes by more than about 5 kg",
              "status": "completed_today",
              "detail": "44.0 kg, BMI 20.1; albumin 4.2 g/dL",
              "observation_ids": [
                "OBS-ALB-V5"
              ],
              "guideline_ids": [
                "GL-ASPEN-MALN-2012"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)",
              "cadence": "Every visit and every observed dose",
              "status": "completed_today",
              "detail": "No symptoms throughout the continuation phase",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests (ALT, AST, bilirubin)",
              "cadence": "Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms",
              "status": "completed_today",
              "detail": "ALT 18, AST 20 U/L at the end of treatment; no tests were needed for symptoms in the continuation phase",
              "observation_ids": [
                "OBS-ALT-V5",
                "OBS-AST-V5"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-HEPATOTOX-2006"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Two-month sputum smear and culture",
              "cadence": "At the end of the intensive phase",
              "status": "completed_today",
              "detail": "Smear negative; no growth at six weeks, as with the two-week culture",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-ATS-TB-2025"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count",
              "cadence": "At diagnosis, then as needed",
              "status": "completed_today",
              "detail": "Hemoglobin 13.2 g/dL, normal",
              "observation_ids": [
                "OBS-HGB-V5"
              ],
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Chest X-ray",
              "cadence": "At diagnosis and at the end of treatment as a new baseline",
              "status": "completed_today",
              "detail": "Opacities cleared, with a few linear scars; new baseline",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Doses observed and missed (video-observed therapy)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "182 of 182 doses observed; treatment completed",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Peripheral neuropathy check, with pyridoxine",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No neuropathy; pyridoxine stopped with isoniazid",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Visual acuity and color vision",
              "cadence": "Baseline and monthly while on ethambutol",
              "status": "not_indicated",
              "detail": "Ethambutol stopped in the fifth week; acuity normal at two months",
              "guideline_ids": [
                "GL-ATS-TB-2016",
                "GL-WHO-TB-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Contact investigation (household and close contacts)",
              "cadence": "Led by the public health center, from diagnosis",
              "status": "completed_today",
              "detail": "The public health center reports the investigation complete; results are held in the contacts' own records",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY",
                "GL-CDC-CONTACT-2005"
              ]
            },
            {
              "domain": "referral",
              "measure": "Report of treatment outcome to the public health center",
              "cadence": "At the end of treatment",
              "status": "completed_today",
              "detail": "Treatment completed reported",
              "guideline_ids": [
                "GL-MHLW-TB-NOTIFY"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At diagnosis, at two months, and at the end of treatment",
              "status": "completed_today",
              "detail": "PHQ-9 3, item 9 scored 0",
              "observation_ids": [
                "OBS-PHQ9-V5"
              ],
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Hepatitis B, HPV and influenza vaccines",
              "cadence": "Hepatitis B in two doses four weeks or more apart; HPV in three doses; influenza each autumn",
              "status": "completed_today",
              "detail": "Hepatitis B dose 2 (series complete), HPV dose 2 and influenza vaccine given today; HPV dose 3 due in four months",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            }
          ],
          "follow_up": "No routine tuberculosis follow-up; return for symptoms. HPV dose 3 in four months. Next preventive visit in about ten months",
          "guideline_ids": [
            "GL-ATS-TB-2016",
            "GL-ATS-TB-2025",
            "GL-WHO-TB-2022",
            "GL-ATS-HEPATOTOX-2006",
            "GL-CDC-CONTACT-2005",
            "GL-MHLW-TB-NOTIFY",
            "GL-ASPEN-MALN-2012",
            "GL-USPSTF-DEP-2023",
            "GL-CDC-IMZ-2026"
          ]
        }
      },
      {
        "id": "ENC-006",
        "display": "Same-day sick visit for acute cystitis during tuberculosis treatment",
        "status": "finished",
        "date": "2026-07-20",
        "visit_type": "sick",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "185345009",
          "display": "Encounter for symptom",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Burning on passing urine for two days",
          "billing_note": "Problem-oriented office visit, established patient",
          "hpi": {
            "narrative": "Ms. Higuchi called this morning and was seen the same day. For two days she has had burning when she passes urine, needing to go often and urgently, and a dull ache low in her abdomen. She has no fever, chills, back or flank pain, nausea or vomiting, and no vaginal discharge or itching. She has never had a urinary infection before. She has not been sexually active and is not pregnant. She admits she has been drinking little while writing for long stretches at her desk on hot days. She is in the fourteenth week of tuberculosis treatment, in the continuation phase on isoniazid and rifampin, and has taken every dose on video with the public health center; her urine is orange from rifampin, as expected. Her cough has gone and she is gaining weight.",
            "elements": [
              {
                "label": "Onset",
                "value": "Two days ago"
              },
              {
                "label": "Symptoms",
                "value": "Burning, frequency, urgency and lower abdominal ache"
              },
              {
                "label": "Severity",
                "value": "Moderate; no fever"
              },
              {
                "label": "Context",
                "value": "Continuation phase of tuberculosis treatment on isoniazid and rifampin; drinking little"
              },
              {
                "label": "Associated signs and symptoms",
                "value": "No flank pain, fever, vomiting or vaginal discharge"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, chills or night sweats"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Dysuria, frequency and urgency for two days; urine orange from rifampin; no visible blood"
            },
            {
              "system": "Gastrointestinal",
              "status": "positive",
              "finding": "Dull suprapubic ache; no nausea, vomiting or abdominal pain elsewhere"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or sputum"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No back or flank pain"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Comfortable; temperature 37.0 °C, pulse 84, blood pressure 104/66; weight 42.0 kg"
            },
            {
              "system": "Abdomen",
              "finding": "Mild suprapubic tenderness; soft; liver not enlarged or tender"
            },
            {
              "system": "Back",
              "finding": "No costovertebral angle tenderness"
            },
            {
              "system": "Eyes",
              "finding": "No icterus"
            },
            {
              "system": "Skin",
              "finding": "No rash"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-005",
              "display": "Acute uncomplicated cystitis",
              "assessment": "Typical lower urinary symptoms with no fever or flank pain: uncomplicated cystitis. Rifampin colors the urine orange-red and can make the color pads of a dipstick unreliable, so a clean-catch sample was sent for microscopy and culture rather than relying on the strip; microscopy shows many white cells and bacteria. Pregnancy test negative. Nitrofurantoin is first-line, does not interact with isoniazid or rifampin, and her kidney function is normal. A fluoroquinolone is avoided: these drugs are kept for drug-resistant tuberculosis, and courses of them can mask tuberculosis or select resistance",
              "plan": [
                "Nitrofurantoin 100 mg twice daily with food for five days",
                "Urine culture; result by phone",
                "At least two liters of fluid a day, with a jug on her writing desk",
                "Return for fever, flank pain, vomiting, or no improvement in two days"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, continuation phase",
              "assessment": "Every dose taken; no cough, fever or night sweats; no jaundice, nausea or numbness. No interaction between nitrofurantoin and her tuberculosis medicines",
              "plan": [
                "Continue isoniazid, rifampin and pyridoxine by video-observed therapy without a break"
              ]
            }
          ],
          "follow_up": "Culture result by phone. Preventive visit in five weeks as booked. Return sooner for fever or flank pain",
          "guideline_ids": [
            "GL-IDSA-UTI-2010",
            "GL-ATS-TB-2016"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic unscheduled sick visit; the cystitis is not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "ENC-007",
        "display": "Periodic adult preventive visit",
        "status": "finished",
        "date": "2026-08-24",
        "visit_type": "preventive_adult",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "86013001",
          "display": "Periodic reevaluation and management of healthy individual",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Periodic adult preventive visit",
          "billing_note": "CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning) on the same day",
          "health_risk_assessment_method": "Completed by the patient on paper in the waiting room and reviewed with her by Dr. Lindgren-Tanaka",
          "hpi": {
            "narrative": "Ms. Higuchi is a 24-year-old writer with drug-susceptible pulmonary tuberculosis in the nineteenth week of treatment, now in the continuation phase on isoniazid, rifampin and pyridoxine by video-observed therapy, who comes for the preventive visit booked at her first appointment. Her cough and night sweats have gone, she sleeps well, and she has gained 4 kg since intake. The cystitis five weeks ago settled within two days on nitrofurantoin, and the culture grew Escherichia coli susceptible to it. The sputum culture taken at the end of the intensive phase showed no growth after six weeks. She writes about two hours each morning and has finished a new story. Public funding now covers most of her tuberculosis costs, and the social worker helped her arrange to pay her clinic charges in instalments. She has no new concerns.",
            "elements": [
              {
                "label": "Visit",
                "value": "Periodic adult preventive visit, age 24"
              },
              {
                "label": "Tuberculosis",
                "value": "Week 19 of 26; no symptoms; every dose taken"
              },
              {
                "label": "Cystitis",
                "value": "Resolved"
              },
              {
                "label": "Mood",
                "value": "PHQ-2 1; GAD-7 4"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Good and improving"
            },
            {
              "domain": "Psychosocial",
              "finding": "Money is her main stress; less worried now that treatment costs are covered; feels supported by her editors and readers"
            },
            {
              "domain": "Substance use",
              "finding": "AUDIT-C 0; no drug use"
            },
            {
              "domain": "Tobacco",
              "finding": "Never smoked; no one smokes at home"
            },
            {
              "domain": "Physical activity",
              "finding": "Walks to the market and back most days, about 30 minutes"
            },
            {
              "domain": "Nutrition",
              "finding": "Three meals and two snacks a day with two supplement drinks; more fish, eggs and tofu since the dietitian visits"
            },
            {
              "domain": "Sleep",
              "finding": "Seven hours; writing moved from night to morning"
            },
            {
              "domain": "Safety",
              "finding": "Feels safe at home; intimate partner violence screen negative; smoke alarm at home"
            },
            {
              "domain": "Sexual and reproductive health",
              "finding": "Not sexually active; not planning a pregnancy; regular periods"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, night sweats or weight loss; weight rising"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No change in vision or color vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No sore throat or hearing change"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No chest pain or palpitations"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough, sputum or breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No nausea, abdominal pain or jaundice"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No urinary symptoms since the cystitis; urine orange from rifampin"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No joint pain"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No numbness or tingling in the hands or feet"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood good; PHQ-2 1"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Slim and well; weight 42.6 kg, BMI 19.4; blood pressure 104/66"
            },
            {
              "system": "Eyes",
              "finding": "No icterus; conjunctivae pink"
            },
            {
              "system": "Neck",
              "finding": "No enlarged lymph nodes; thyroid normal"
            },
            {
              "system": "Respiratory",
              "finding": "Clear on both sides"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; no murmur"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; liver not enlarged"
            },
            {
              "system": "Genitourinary",
              "finding": "Speculum examination with a small speculum, with a chaperone and her consent: normal cervix; cytology sample taken"
            },
            {
              "system": "Neurological",
              "finding": "Normal sensation and reflexes in the feet"
            }
          ],
          "assessment_plan": [
            {
              "display": "Periodic adult preventive visit completed",
              "assessment": "Health risk assessment reviewed and the prevention plan updated. First cervical screening done. Tdap, the first hepatitis B dose and the first HPV dose given. HIV, hepatitis B and hepatitis C screening were done at intake",
              "plan": [
                "Cervical cytology result by phone; repeat in three years if normal",
                "Hepatitis B dose 2 and HPV dose 2 at the end-of-treatment visit; HPV dose 3 six months after the first",
                "Influenza vaccine at the end-of-treatment visit",
                "Next preventive visit in one year"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Pulmonary tuberculosis, continuation phase",
              "assessment": "Week 19 of 26 with no symptoms. Rifampin speeds the breakdown of the hormones in combined pills, patches, rings and implants and makes them unreliable",
              "plan": [
                "If she needs contraception during treatment or for four weeks after, a copper IUD, an injectable progestin or condoms are reliable",
                "Continue every dose; end-of-treatment visit after the 182nd dose"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Moderate protein-calorie malnutrition, improving",
              "assessment": "Weight 42.6 kg from 38.5 kg at intake; BMI 19.4",
              "plan": [
                "Continue the meal plan and supplement drinks until her weight reaches 44 kg"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Low income",
              "assessment": "Public funding covers most tuberculosis costs; clinic charges are paid in instalments",
              "plan": [
                "Social worker to review her costs again at the end of treatment"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Blood pressure screening",
              "status": "completed_today",
              "detail": "104/66 mmHg",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-2 score 1",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "service": "Anxiety screening",
              "status": "completed_today",
              "detail": "GAD-7 score 4",
              "guideline_ids": [
                "GL-USPSTF-ANX-2023"
              ]
            },
            {
              "service": "Unhealthy alcohol use screening",
              "status": "completed_today",
              "detail": "AUDIT-C score 0",
              "guideline_ids": [
                "GL-USPSTF-ALC-2018"
              ]
            },
            {
              "service": "Tobacco use",
              "status": "completed_today",
              "detail": "Never smoked",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Intimate partner violence screening",
              "status": "completed_today",
              "detail": "Asked privately; negative",
              "guideline_ids": [
                "GL-USPSTF-IPV-2018"
              ]
            },
            {
              "service": "Cervical cancer screening",
              "status": "completed_today",
              "detail": "Cytology at 24, her first screening; every three years from 21 to 29",
              "guideline_ids": [
                "GL-USPSTF-CERV-2018"
              ]
            },
            {
              "service": "Chlamydia and gonorrhea screening",
              "status": "not_indicated",
              "detail": "Not sexually active; offer when that changes, as for sexually active women 24 or younger",
              "guideline_ids": [
                "GL-USPSTF-CTGC-2021"
              ]
            },
            {
              "service": "Contraception and pregnancy intention",
              "status": "completed_today",
              "detail": "Not planning a pregnancy; counseled on the rifampin interaction with hormonal methods",
              "guideline_ids": [
                "GL-CDC-SPR-2024"
              ]
            },
            {
              "service": "Folic acid",
              "status": "completed_today",
              "detail": "Advised 0.4 to 0.8 mg daily, as for anyone who could become pregnant",
              "guideline_ids": [
                "GL-USPSTF-FOLIC-2023"
              ]
            },
            {
              "service": "HIV screening",
              "status": "up_to_date",
              "detail": "Negative at intake",
              "guideline_ids": [
                "GL-USPSTF-HIV-2019"
              ]
            },
            {
              "service": "Hepatitis C screening",
              "status": "up_to_date",
              "detail": "Negative at intake",
              "guideline_ids": [
                "GL-USPSTF-HCV-2020"
              ]
            },
            {
              "service": "Hepatitis B screening",
              "status": "up_to_date",
              "detail": "At intake: surface antigen, surface antibody and core antibody negative; not immune",
              "guideline_ids": [
                "GL-CDC-HBV-2023"
              ]
            },
            {
              "service": "Diabetes screening",
              "status": "up_to_date",
              "detail": "Hemoglobin A1c 5.1% at intake, checked because diabetes worsens tuberculosis outcomes",
              "guideline_ids": [
                "GL-ATS-TB-2016"
              ]
            },
            {
              "service": "Tetanus, diphtheria, and pertussis",
              "status": "completed_today",
              "detail": "Tdap; no adult booster recorded",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Hepatitis B vaccine",
              "status": "completed_today",
              "detail": "Dose 1 of 2 today; dose 2 in eight weeks",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "HPV vaccine",
              "status": "completed_today",
              "detail": "Catch-up dose 1 of 3 today, through age 26",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Influenza vaccine",
              "status": "due",
              "detail": "In the autumn, at the end-of-treatment visit",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "COVID-19 vaccine",
              "status": "due",
              "detail": "Discuss in the autumn",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 16 minutes, with her consent. She understands that her tuberculosis is curable and wants full treatment of any illness. She named a health care agent, recorded in the confidential part of the chart and not named here, and chose to record no other preferences today. To be revisited yearly.",
          "follow_up": "End-of-treatment visit after the 182nd dose, with the chest X-ray, blood tests, the second hepatitis B and HPV doses and the influenza vaccine. Cytology result by phone. Next preventive visit in one year",
          "guideline_ids": [
            "GL-PREV-2026",
            "GL-USPSTF-AB",
            "GL-CDC-IMZ-2026",
            "GL-USPSTF-CERV-2018",
            "GL-CDC-SPR-2024"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic periodic preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-04-14",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 38.5,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 17.6,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 98,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 62,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 104,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 20,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 37.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic seated vital signs with low-grade fever and a fast pulse, taken in an airborne infection isolation room.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-04-17",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 38.4,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 17.5,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 96,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 60,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 100,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 20,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 37.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, taken in an airborne infection isolation room.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-05-01",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 39.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 17.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 100,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 62,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 90,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 18,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 37.1,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-06-12",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 41.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 18.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 102,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 64,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 80,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-10-20",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 44.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 20.1,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 106,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 68,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 72,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.5,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-006",
        "date": "2026-07-20",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 42.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 19.2,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 104,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 66,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 84,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 37.0,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs at the sick visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "VSET-007",
        "date": "2026-08-24",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 148,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 42.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 19.4,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 104,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 66,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Writer of short fiction and essays, paid by the piece by literary magazines; writes at home at a low desk, mostly at night; finished several stories in the past year and is working on new ones with editors waiting",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic modern work history anchored to her documented writing career and productive period.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Head of a household of three adults in a small rented house in Hongō, Tokyo; provides for the household from her writing income, which is low and irregular, with unpaid bills; enrolled in National Health Insurance",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic household and finances anchored to her documented support of her household and poverty; no decision, statement or health fact is attributed to any relative.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Never smoked; no alcohol (AUDIT-C 0); no drug use; no travel outside Japan; no incarceration, homelessness or work in health care; not sexually active",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic risk-factor history for tuberculosis, HIV testing and liver risk.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Meals irregular and small, mostly rice, pickles and tea, with fish or tofu a few times a week when money allows",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic diet history.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "Supports and strengths she names: her writing, her readers and editors, and the poetry she studied when young",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic strengths; no relative is given a role.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "Independent; too tired over the past month to write for more than an hour or two, and short of breath on the stairs",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic functional status.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Alert, composed and precise in her answers, with a wry humor; thin and tired; organized thought",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "MSE-002",
        "display": "Mood worried about money, her household and her deadlines; PHQ-9 8, with item 9 scored 0; no thoughts of suicide or self-harm",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding; not a claim about her real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "consultation": {
      "referral": {
        "question": "Suspected pulmonary tuberculosis in a 23-year-old writer with seven weeks of cough, evening fevers, night sweats and 10 percent weight loss, and right upper lobe opacities without a cavity. Please see her at the results visit in three days to confirm the diagnosis, choose the regimen and doses, and advise on monitoring and infection control",
        "urgency": "Urgent, at the results visit in three days. She is not short of breath at rest (oxygen saturation 96 percent) and has no hemoptysis. She is on airborne precautions at home, and the public health center has been told of the suspected case today",
        "pertinent_history": "Cough for about seven weeks with a little white sputum, evening fevers, night sweats, poor appetite and weight loss of about 4 kg to 38.5 kg (BMI 17.6). No hemoptysis. No known tuberculosis contact, travel, HIV risk, diabetes, or immune-suppressing medicine; never smoked; no alcohol. No medicines and no known allergy. Lives with two adults in a small rented house; writes at home; low and irregular income. Today: temperature 37.8 °C, pulse 104, blood pressure 98/62, respiratory rate 20, oxygen saturation 96 percent; fine crackles over the right upper zone. Chest X-ray: patchy opacities and small nodules in the apical and posterior segments of the right upper lobe; no cavity or effusion. Three sputum specimens for smear, Xpert MTB/RIF Ultra and culture: the first collected today, two to follow. Hemoglobin 11.4 g/dL, white cells 8.6, platelets 452; ALT 12, AST 19, bilirubin 0.4, alkaline phosphatase 74, albumin 3.3 g/dL; creatinine 0.56 mg/dL; glucose 82 mg/dL; hemoglobin A1c 5.1%. Visual acuity 85 letters in each eye with normal color vision. HIV, hepatitis B and C, and pregnancy tests sent. PHQ-9 8, item 9 scored 0",
        "questions": [
          "Do her results confirm pulmonary tuberculosis if the sputum smears are negative?",
          "Which regimen do you advise: the standard six-month regimen or the four-month rifapentine-moxifloxacin regimen, and at what doses for her weight?",
          "Can she be treated as an outpatient, and when can she stop the precautions at home?",
          "What monitoring do you advise for liver injury, given her low weight and albumin, and for vision on ethambutol?",
          "When can ethambutol be stopped, and how long should the continuation phase be?",
          "What should the public health center's contact investigation cover?"
        ]
      },
      "consultant_note": {
        "history": "Ms. Higuchi, a 23-year-old writer, is seen at the request of Dr. Lindgren-Tanaka at her results visit three days after her first visit. She describes about seven weeks of cough with a little white sputum, evening fevers, night sweats and weight loss, and she has been too tired to write for more than an hour or two. She has no hemoptysis, no known tuberculosis contact, no travel outside Japan, and no condition or medicine that weakens the immune system. She does not smoke or drink and takes no medicines. She lives with two adults and has stayed home with a mask in shared rooms since her first visit. She is anxious about the people she lives with and about the cost of treatment",
        "data_reviewed": "Dr. Lindgren-Tanaka's intake note and results. Chest X-ray: right upper lobe opacities and small nodules without a cavity. Three sputum specimens, one on waking: smears negative for acid-fast bacilli; Xpert MTB/RIF Ultra on the first specimen detected Mycobacterium tuberculosis at a low level with no rifampin resistance; cultures pending. HIV antigen and antibody test, hepatitis B surface antigen and core antibody, hepatitis C antibody and pregnancy test negative; hepatitis B surface antibody negative. Liver and kidney tests normal; albumin 3.3 g/dL; hemoglobin 11.4 g/dL; hemoglobin A1c 5.1%. Visual acuity 85 letters in each eye; color vision normal. Weight today 38.4 kg",
        "exam": [
          {
            "system": "General",
            "finding": "Thin and tired; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room"
          },
          {
            "system": "Respiratory",
            "finding": "Fine crackles over the right upper zone"
          },
          {
            "system": "Eyes",
            "finding": "No icterus"
          },
          {
            "system": "Abdomen",
            "finding": "Liver not enlarged"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-002",
            "display": "Pulmonary tuberculosis, smear-negative, Xpert-confirmed",
            "assessment": "A positive Xpert MTB/RIF Ultra result in a patient with this history and X-ray confirms pulmonary tuberculosis even with negative smears; treatment should start today and not wait for culture. No rifampin resistance was detected and she has no risk factors for drug resistance. Smear-negative disease without a cavity carries a lower bacterial load and a lower risk of transmission"
          },
          {
            "problem_id": "PRB-002",
            "display": "Regimen choice",
            "assessment": "The four-month rifapentine-moxifloxacin regimen requires a body weight of at least 40 kg, and she weighs 38.4 kg, so she is not eligible; the standard six-month regimen is recommended. Doses: isoniazid 200 mg (about 5 mg/kg), rifampin 450 mg (about 12 mg/kg, within the WHO range of 8 to 12 mg/kg, using 150 mg capsules), pyrazinamide 1000 mg (about 26 mg/kg) and ethambutol 600 mg (about 16 mg/kg), with pyridoxine because of her poor nutrition. Doses are reviewed if her weight changes by more than about 5 kg"
          },
          {
            "problem_id": "PRB-003",
            "display": "Moderate malnutrition and liver risk",
            "assessment": "Low weight and albumin raise the risk of drug-induced liver injury, so liver tests at two weeks and monthly in the intensive phase are advised, in addition to symptom checks at every observed dose. If tests stay normal and albumin recovers, testing in the continuation phase can be for symptoms only"
          }
        ],
        "recommendations": [
          "Start isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg, ethambutol 600 mg and pyridoxine 50 mg daily today, by daily video-observed therapy with the public health center",
          "Outpatient treatment is appropriate for smear-negative disease without a cavity in a patient who can stay home; continue home precautions until she has had two weeks of treatment and is improving, then end them with the public health center's agreement",
          "Liver tests at two weeks and monthly in the intensive phase; visual acuity and color vision at two weeks and monthly while on ethambutol; stop the drugs and call the same day for hepatitis symptoms or any change in vision",
          "Stop ethambutol as soon as the isolate is shown to be susceptible to isoniazid and rifampin",
          "Sputum smear and culture at two weeks and at two months; without a cavity the continuation phase is four months of isoniazid and rifampin; consider seven months if the two-month culture is positive, because she is underweight",
          "Notify the public health center at once on diagnosis; its contact investigation should cover the household first, then other close contacts with hours of shared indoor air during the infectious period, such as visiting editors",
          "Counsel her that rifampin makes hormonal contraceptives unreliable and interacts with many medicines; avoid fluoroquinolones for other infections during treatment",
          "Chest X-ray at the end of treatment as a new baseline"
        ],
        "communication": "Discussed with Dr. Lindgren-Tanaka the same morning; she continues the prescribing and monitoring with the public health center. Ms. Higuchi was told that tuberculosis is curable with six months of treatment, that she will soon stop being infectious, and that most of the costs are covered by public funding; she asked how soon she could write again and was encouraged to begin with short sessions once the fevers settle",
        "follow_up": "Available by phone to Dr. Lindgren-Tanaka for the susceptibility results and any adverse effect; review again if a drug has to be stopped"
      },
      "guideline_ids": [
        "GL-ATS-TB-2016",
        "GL-ATS-TB-2025",
        "GL-WHO-TB-2022",
        "GL-ATS-TBDX-2017",
        "GL-CDC-4MO-2022",
        "GL-ATS-HEPATOTOX-2006",
        "GL-CDC-CONTACT-2005",
        "GL-MHLW-TB-NOTIFY"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "She supports her household by writing and cannot afford to stop working or to pay for many tests",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to her documented poverty.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "Complete 182 daily doses within about six and a half months by video-observed therapy",
        "status": "completed",
        "target_date": "2026-10-20",
        "outcome": "All 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missed",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic treatment-completion goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "Sputum culture negative at two months",
        "status": "completed",
        "target_date": "2026-10-20",
        "outcome": "The cultures taken at two weeks and at two months both showed no growth after six weeks",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic culture-conversion goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "Weight at least 44 kg (BMI about 20) by the end of treatment",
        "status": "completed",
        "target_date": "2026-10-20",
        "outcome": "44.0 kg at the end of treatment, from 38.5 kg at intake",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic nutrition goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "Keep writing on a paced schedule without losing income during treatment",
        "status": "completed",
        "target_date": "2026-10-20",
        "outcome": "Public funding covered most treatment costs; she kept writing about two hours a day and finished new work",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic occupational and financial goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "No drug-induced liver injury or loss of vision during treatment",
        "status": "completed",
        "target_date": "2026-10-20",
        "outcome": "Liver tests normal throughout; visual acuity unchanged",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic safety goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Diagnosis and safety: chest X-ray; three sputum specimens at least eight hours apart, one early in the morning, for acid-fast smear, Xpert MTB/RIF Ultra, liquid and solid culture and drug susceptibility testing; HIV, hepatitis B and hepatitis C tests and a pregnancy test; blood count, liver and kidney tests, glucose and hemoglobin A1c; visual acuity and color vision before ethambutol",
        "status": "completed",
        "guideline_ids": [
          "GL-ATS-TBDX-2017",
          "GL-ATS-TB-2016",
          "GL-WHO-TB-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic diagnostic plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Infectious diseases consultation at the results visit to confirm the diagnosis, choose between the six-month and four-month regimens, set the doses for her weight, and plan monitoring and infection control",
        "status": "completed",
        "guideline_ids": [
          "GL-ATS-TB-2016",
          "GL-ATS-TB-2025",
          "GL-CDC-4MO-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "Infection control and public health: airborne precautions in the clinic; at home, no visitors, a surgical mask in shared rooms, windows open, and sleeping in her own room until the public health center confirms she is no longer infectious; report of suspected tuberculosis to the public health center the same day and notification at once on diagnosis; a contact investigation of her household and other close contacts led by the public health center",
        "status": "completed",
        "guideline_ids": [
          "GL-MHLW-TB-NOTIFY",
          "GL-CDC-CONTACT-2005",
          "GL-ATS-TB-2016"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic public-health plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "INT-004",
        "display": "Nutrition, income and writing: two dietitian visits in the first month, three meals and two energy-dense snacks a day with two oral nutrition supplement drinks, and weight at every visit; a medical social worker to apply for public funding of tuberculosis treatment and to review other help with costs; a paced writing plan of short sessions in daylight with rest; PHQ-9 at intake, at two months and at the end of treatment",
        "status": "completed",
        "guideline_ids": [
          "GL-ASPEN-MALN-2012",
          "GL-JP-TB-FUNDING",
          "GL-USPSTF-DEP-2023"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic support plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        }
      },
      {
        "id": "INT-005",
        "display": "Treatment: isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily for eight weeks, then isoniazid and rifampin daily for eighteen weeks, with pyridoxine 50 mg, by daily video-observed therapy with the public health center; ethambutol stopped once the isolate is susceptible to isoniazid and rifampin; liver tests at two weeks and monthly in the intensive phase because of her low weight and albumin; visual acuity and color vision monthly while on ethambutol; sputum smear and culture at two weeks and two months; chest X-ray at the end of treatment",
        "status": "completed",
        "guideline_ids": [
          "GL-ATS-TB-2016",
          "GL-ATS-TB-2025",
          "GL-WHO-TB-2022",
          "GL-ATS-HEPATOTOX-2006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0010",
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic treatment and monitoring plan decided at the results visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "recorded_date": "2026-04-17"
      },
      {
        "id": "INT-006",
        "display": "Acute cystitis: nitrofurantoin 100 mg twice daily for five days with urine culture; no fluoroquinolone, because these drugs are kept for drug-resistant tuberculosis and can blur the picture of tuberculosis; continue every tuberculosis dose; plenty of fluids; return for fever, flank pain, vomiting or symptoms that are not better in two days",
        "status": "completed",
        "guideline_ids": [
          "GL-IDSA-UTI-2010",
          "GL-ATS-TB-2016"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic plan decided at the sick visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "recorded_date": "2026-07-20"
      },
      {
        "id": "INT-007",
        "display": "Prevention: cervical cytology now and every three years; Tdap; hepatitis B vaccine in two doses and HPV vaccine in three doses; influenza vaccine in the autumn; folic acid 0.4 mg daily advised; contraception counseling that rifampin makes hormonal pills, patches, rings and implants unreliable, with a copper IUD, injectable progestin or condoms as reliable choices if she needs contraception during treatment",
        "status": "completed",
        "guideline_ids": [
          "GL-USPSTF-CERV-2018",
          "GL-CDC-IMZ-2026",
          "GL-CDC-SPR-2024",
          "GL-USPSTF-FOLIC-2023"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic prevention plan decided at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T12:00:00-05:00"
        },
        "recorded_date": "2026-08-24"
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-ATS-TB-2016",
        "title": "Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis",
        "publisher": "American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/27516382/",
        "version_or_year": "2016"
      },
      {
        "guideline_id": "GL-ATS-TB-2025",
        "title": "Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline",
        "publisher": "American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine 2025;211(1):15-33)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40693952/",
        "version_or_year": "2025"
      },
      {
        "guideline_id": "GL-WHO-TB-2022",
        "title": "WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment",
        "publisher": "World Health Organization",
        "url": "https://www.who.int/publications/i/item/9789240048126",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-ATS-TBDX-2017",
        "title": "Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children",
        "publisher": "American Thoracic Society, Infectious Diseases Society of America, and Centers for Disease Control and Prevention (Clinical Infectious Diseases)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/28052967/",
        "version_or_year": "2017"
      },
      {
        "guideline_id": "GL-CDC-4MO-2022",
        "title": "Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022",
        "publisher": "Centers for Disease Control and Prevention (MMWR)",
        "url": "https://www.cdc.gov/mmwr/volumes/71/wr/mm7108a1.htm",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-ATS-HEPATOTOX-2006",
        "title": "An official ATS statement: hepatotoxicity of antituberculosis therapy",
        "publisher": "American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/17021358/",
        "version_or_year": "2006"
      },
      {
        "guideline_id": "GL-CDC-CONTACT-2005",
        "title": "Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC",
        "publisher": "Centers for Disease Control and Prevention (MMWR Recommendations and Reports)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/16357823/",
        "version_or_year": "2005"
      },
      {
        "guideline_id": "GL-MHLW-TB-NOTIFY",
        "title": "結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law",
        "publisher": "Ministry of Health, Labour and Welfare, Japan",
        "url": "https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-02-02.html",
        "version_or_year": "current"
      },
      {
        "guideline_id": "GL-JP-TB-FUNDING",
        "title": "結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law)",
        "publisher": "Niigata Prefecture, Japan",
        "url": "https://www.pref.niigata.lg.jp/sec/kanyaku/1356823070494.html",
        "version_or_year": "current"
      },
      {
        "guideline_id": "GL-ASPEN-MALN-2012",
        "title": "Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition)",
        "publisher": "Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/22535923/",
        "version_or_year": "2012"
      },
      {
        "guideline_id": "GL-USPSTF-DEP-2023",
        "title": "Depression and Suicide Risk in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-IDSA-UTI-2010",
        "title": "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases",
        "publisher": "Infectious Diseases Society of America (Clinical Infectious Diseases 2011;52(5):e103-e120)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/21292654/",
        "version_or_year": "2010"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-AB",
        "title": "USPSTF A and B Recommendations",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-CERV-2018",
        "title": "Cervical Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-ANX-2023",
        "title": "Anxiety Disorders in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-USPSTF-ALC-2018",
        "title": "Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-IPV-2018",
        "title": "Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-FOLIC-2023",
        "title": "Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-USPSTF-CTGC-2021",
        "title": "Chlamydia and Gonorrhea: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-USPSTF-HIV-2019",
        "title": "Human Immunodeficiency Virus (HIV) Infection: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-USPSTF-HCV-2020",
        "title": "Hepatitis C Virus Infection in Adolescents and Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-CDC-HBV-2023",
        "title": "Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, United States, 2023",
        "publisher": "Centers for Disease Control and Prevention (MMWR Recommendations and Reports)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36893044/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-CDC-SPR-2024",
        "title": "U.S. Selected Practice Recommendations for Contraceptive Use, 2024",
        "publisher": "Centers for Disease Control and Prevention (MMWR Recommendations and Reports)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39106301/",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check outpatient care for smear-negative, Xpert-positive disease in Japan, the six-month regimen chosen because her weight is below 40 kg, the weight-based doses, liver monitoring in a malnourished woman, and the recorded gap in month-one monitoring."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "National Diet Library portrait biography and calendar page, Kotobank encyclopedia entries (Nipponica and others), Nippon.com, the Ichiyō Memorial Museum page, the Bunkyō City biography, and the Bank of Japan banknote page logged. Danly's biography was not read. The form of her fatal tuberculosis differs between sources (pulmonary or miliary)."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "No psychiatric claim is made; PHQ-9 at most 8 with item 9 scored 0, so no safety assessment is required. Her mother and sister appear only in documented history; the household contact investigation names no one and records no result. Her death is recorded in one sentence."
    }
  }
}
